Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOSPECIFICS TECHNOLOGIES CORPBSTC · Entity 144844 | SVP Business Development | January 23, 2019 | February 01, 2019 |
| ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311 | Chief Strategy Officer | March 20, 2017 | March 21, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOSPECIFICS TECHNOLOGIES CORP
Report date January 23, 2019 · Filed February 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.48 · Expires 2028-11-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-23 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: This stock option is exercisable in four equal annual installments commencing on November 15, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option is exercisable in four equal annual installments commencing on November 15, 2019.
ORAMED PHARMACEUTICALS INC.
Report date March 20, 2017 · Filed March 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2027-03-20 | Direct | 37,152 |
Reported balance
After 2017-03-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-20 · Grant · Acquired 37,152 · Balance 37,152 F1: The Stock Option shall vest in 24 consecutive equal monthly installments commencing March 31, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option shall vest in 24 consecutive equal monthly installments commencing March 31, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2017 Filed Mar 21, 2017 16:09 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 37,152 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001213900-17-002644 · f4032017law_oramedpharma.xml · derivative · entry 1 Law Ronald Edward · CIK 0001701348 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,152 Underlying: Common Stock · 37,152 shares Expires 2027-03-20 F1 · derivative.exercise_date: The Stock Option shall vest in 24 consecutive equal monthly installments commencing March 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.